-
2
-
-
63049133092
-
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
-
Altekruse SF, McGlynn KA, Reichman ME., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 9: 1485-91.
-
(2009)
J Clin Oncol
, vol.9
, pp. 1485-1491
-
-
Altekruse, S.F.1
McGlynn, K.A.2
Reichman, M.E.3
-
3
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 4: 378-90.
-
(2008)
N Engl J Med
, vol.4
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
4
-
-
39149123547
-
Clinical application of the 70-gene profile: The MINDACT trial
-
Cardoso F, Van't Veer L, Rutgers E, et al., Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 5: 729-35.
-
(2008)
J Clin Oncol
, vol.5
, pp. 729-735
-
-
Cardoso, F.1
Van'T Veer, L.2
Rutgers, E.3
-
5
-
-
39149113165
-
Development of the 21-gene assay and its application in clinical practice and clinical trials
-
Sparano JA, Paik S., Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 5: 721-8.
-
(2008)
J Clin Oncol
, vol.5
, pp. 721-728
-
-
Sparano, J.A.1
Paik, S.2
-
6
-
-
79952438796
-
Genetics: An 18-gene signature (ColoPrint(R)) for colon cancer prognosis
-
Tan IB, Tan P., Genetics: an 18-gene signature (ColoPrint(R)) for colon cancer prognosis. Nat Rev Clin Oncol 2011; 3: 131-3.
-
(2011)
Nat Rev Clin Oncol
, vol.3
, pp. 131-133
-
-
Tan, I.B.1
Tan, P.2
-
7
-
-
41649114164
-
Enabling personalized cancer medicine through analysis of gene-expression patterns
-
van't Veer LJ, Bernards R., Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 7187: 564-70.
-
(2008)
Nature
, vol.7187
, pp. 564-570
-
-
Van'T Veer, L.J.1
Bernards, R.2
-
8
-
-
70349739285
-
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
-
Hoshida Y, Nijman SM, Kobayashi M, et al., Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 18: 7385-92.
-
(2009)
Cancer Res
, vol.18
, pp. 7385-7392
-
-
Hoshida, Y.1
Nijman, S.M.2
Kobayashi, M.3
-
9
-
-
0036234628
-
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer
-
Lee JS, Thorgeirsson SS., Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002; 5: 1134-43.
-
(2002)
Hepatology
, vol.5
, pp. 1134-1143
-
-
Lee, J.S.1
Thorgeirsson, S.S.2
-
10
-
-
42049116522
-
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells
-
Fuchs BC, Fujii T, Dorfman JD, et al., Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 7: 2391-9.
-
(2008)
Cancer Res
, vol.7
, pp. 2391-2399
-
-
Fuchs, B.C.1
Fujii, T.2
Dorfman, J.D.3
-
11
-
-
84863179793
-
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines
-
Zhao H, Desai V, Wang J, et al., Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther 2012; 2: 503-13.
-
(2012)
Mol Cancer Ther
, vol.2
, pp. 503-513
-
-
Zhao, H.1
Desai, V.2
Wang, J.3
-
12
-
-
77949875878
-
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
-
Tovar V, Alsinet C, Villanueva A, et al., IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010; 4: 550-9.
-
(2010)
J Hepatol
, vol.4
, pp. 550-559
-
-
Tovar, V.1
Alsinet, C.2
Villanueva, A.3
-
13
-
-
84876734918
-
Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
-
Finn RS, Aleshin A, Dering J, et al., Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013; 5: 1838-46.
-
(2013)
Hepatology
, vol.5
, pp. 1838-1846
-
-
Finn, R.S.1
Aleshin, A.2
Dering, J.3
-
14
-
-
84876048479
-
Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer
-
Dieci MV, Arnedos M, Andre F, et al., Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-79.
-
(2013)
Discov
, vol.3
, pp. 264-279
-
-
Dieci, M.V.1
Arnedos, M.2
Andre, F.3
-
15
-
-
75149170979
-
Fibroblast growth factor signalling: From development to cancer
-
Turner N, Grose R., Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 2: 116-29.
-
(2010)
Nat Rev Cancer
, vol.2
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
16
-
-
21044443128
-
In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
-
Lee SH, Lopes de Menezes D, Vora J, et al., In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 10: 3633-41.
-
(2005)
Clin Cancer Res
, vol.10
, pp. 3633-3641
-
-
Lee, S.H.1
Lopes De Menezes, D.2
Vora, J.3
-
17
-
-
49649123154
-
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
-
Hilberg F, Roth GJ, Krssak M, et al., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 12: 4774-82.
-
(2008)
Cancer Res
, vol.12
, pp. 4774-4782
-
-
Hilberg, F.1
Roth, G.J.2
Krssak, M.3
-
18
-
-
33645670595
-
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor
-
Bhide RS, Cai ZW, Zhang YZ, et al., Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 7: 2143-6.
-
(2006)
J Med Chem
, vol.7
, pp. 2143-2146
-
-
Bhide, R.S.1
Cai, Z.W.2
Zhang, Y.Z.3
-
19
-
-
0033883776
-
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
-
Laird AD, Vajkoczy P, Shawver LK, et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 15: 4152-60.
-
(2000)
Cancer Res
, vol.15
, pp. 4152-4160
-
-
Laird, A.D.1
Vajkoczy, P.2
Shawver, L.K.3
-
20
-
-
84860120185
-
AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
-
Gavine PR, Mooney L, Kilgour E, et al., AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 8: 2045-56.
-
(2012)
Cancer Res
, vol.8
, pp. 2045-2056
-
-
Gavine, P.R.1
Mooney, L.2
Kilgour, E.3
-
21
-
-
80054900437
-
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase
-
Guagnano V, Furet P, Spanka C, et al., Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 20: 7066-83.
-
(2011)
J Med Chem
, vol.20
, pp. 7066-7083
-
-
Guagnano, V.1
Furet, P.2
Spanka, C.3
-
22
-
-
84871527692
-
A phase i dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
-
Abstract LB-122
-
Wolf J, Camidge RD, Perez JM, et al., A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2012; 8: Abstract LB-122.
-
(2012)
Cancer Res
, pp. 8
-
-
Wolf, J.1
Camidge, R.D.2
Perez, J.M.3
-
23
-
-
0030834170
-
Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues
-
Hughes SE., Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 7: 1005-19.
-
(1997)
J Histochem Cytochem
, vol.7
, pp. 1005-1019
-
-
Hughes, S.E.1
-
24
-
-
84859528536
-
Physiology of FGF15/19
-
Jones SA., Physiology of FGF15/19. Adv Exp Med Biol 2012; 728: 171-82.
-
(2012)
Adv Exp Med Biol
, vol.728
, pp. 171-182
-
-
Jones, S.A.1
-
25
-
-
0037663483
-
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
-
Holt JA, Luo G, Billin AN, et al., Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 13: 1581-91.
-
(2003)
Genes Dev
, vol.13
, pp. 1581-1591
-
-
Holt, J.A.1
Luo, G.2
Billin, A.N.3
-
26
-
-
0036086285
-
A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
-
Nicholes K, Guillet S, Tomlinson E, et al., A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 6: 2295-307.
-
(2002)
Am J Pathol
, vol.6
, pp. 2295-2307
-
-
Nicholes, K.1
Guillet, S.2
Tomlinson, E.3
-
27
-
-
37849029159
-
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
-
Desnoyers LR, Pai R, Ferrando RE, et al., Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 1: 85-97.
-
(2008)
Oncogene
, vol.1
, pp. 85-97
-
-
Desnoyers, L.R.1
Pai, R.2
Ferrando, R.E.3
-
28
-
-
84866171951
-
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
-
French DM, Lin BC, Wang M, et al., Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012; 5: e36713.
-
(2012)
PLoS One
, vol.5
, pp. e36713
-
-
French, D.M.1
Lin, B.C.2
Wang, M.3
-
29
-
-
79952497178
-
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening
-
Sawey ET, Chanrion M, Cai C, et al., Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011; 3: 347-58.
-
(2011)
Cancer Cell
, vol.3
, pp. 347-358
-
-
Sawey, E.T.1
Chanrion, M.2
Cai, C.3
-
30
-
-
84871491773
-
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor
-
Guagnano V, Kauffmann A, Wohrle S, et al., FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 12: 1118-33.
-
(2012)
Cancer Discov
, vol.12
, pp. 1118-1133
-
-
Guagnano, V.1
Kauffmann, A.2
Wohrle, S.3
-
31
-
-
34748917797
-
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
-
Huynh H, Chow PK, Soo KC., AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 2007; 9: 2468-76.
-
(2007)
Mol Cancer Ther
, vol.9
, pp. 2468-2476
-
-
Huynh, H.1
Chow, P.K.2
Soo, K.C.3
-
32
-
-
33846846541
-
Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas
-
Zucman-Rossi J, Benhamouche S, Godard C, et al., Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007; 5: 774-80.
-
(2007)
Oncogene
, vol.5
, pp. 774-780
-
-
Zucman-Rossi, J.1
Benhamouche, S.2
Godard, C.3
-
33
-
-
77349092851
-
Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements
-
Hoshida Y, Toffanin S, Lachenmayer A, et al., Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 1: 35-51.
-
(2010)
Semin Liver Dis
, vol.1
, pp. 35-51
-
-
Hoshida, Y.1
Toffanin, S.2
Lachenmayer, A.3
-
34
-
-
46249085489
-
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer
-
Coulouarn C, Factor VM, Thorgeirsson SS., Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008; 6: 2059-67.
-
(2008)
Hepatology
, vol.6
, pp. 2059-2067
-
-
Coulouarn, C.1
Factor, V.M.2
Thorgeirsson, S.S.3
-
35
-
-
42249087302
-
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma
-
Woo HG, Park ES, Cheon JH, et al., Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Can Res 2008; 7: 2056-64.
-
(2008)
Clin Can Res
, vol.7
, pp. 2056-2064
-
-
Woo, H.G.1
Park, E.S.2
Cheon, J.H.3
-
36
-
-
40449099255
-
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma
-
Yamashita T, Forgues M, Wang W, et al., EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 5: 1451-61.
-
(2008)
Cancer Res
, vol.5
, pp. 1451-1461
-
-
Yamashita, T.1
Forgues, M.2
Wang, W.3
-
37
-
-
35948981211
-
Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma
-
Wang SM, Ooi LL, Hui KM., Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Can Res 2007; 21: 6275-83.
-
(2007)
Clin Can Res
, vol.21
, pp. 6275-6283
-
-
Wang, S.M.1
Ooi, L.L.2
Hui, K.M.3
-
38
-
-
4444286417
-
Molecular-based prediction of early recurrence in hepatocellular carcinoma
-
Kurokawa Y, Matoba R, Takemasa I, et al., Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004; 2: 284-91.
-
(2004)
J Hepatol
, vol.2
, pp. 284-291
-
-
Kurokawa, Y.1
Matoba, R.2
Takemasa, I.3
-
39
-
-
0032822672
-
FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4
-
Xie MH, Holcomb I, Deuel B, et al., FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 10: 729-35.
-
(1999)
Cytokine
, vol.10
, pp. 729-735
-
-
Xie, M.H.1
Holcomb, I.2
Deuel, B.3
-
40
-
-
34247565954
-
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members
-
Goetz R, Beenken A, Ibrahimi OA, et al., Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 9: 3417-28.
-
(2007)
Mol Cell Biol
, vol.9
, pp. 3417-3428
-
-
Goetz, R.1
Beenken, A.2
Ibrahimi, O.A.3
-
41
-
-
77949328590
-
FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation
-
Wu X, Ge H, Lemon B, et al., FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 8: 5165-70.
-
(2010)
J Biol Chem
, vol.8
, pp. 5165-5170
-
-
Wu, X.1
Ge, H.2
Lemon, B.3
-
42
-
-
33751115468
-
Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man
-
Lundasen T, Galman C, Angelin B, et al., Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 6: 530-6.
-
(2006)
J Intern Med
, vol.6
, pp. 530-536
-
-
Lundasen, T.1
Galman, C.2
Angelin, B.3
-
43
-
-
18244409687
-
Gene expression profiling predicts clinical outcome of breast cancer
-
Van 't Veer LJ, Dai H, van de Vijver MJ, et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 6871: 530-6.
-
(2002)
Nature
, vol.6871
, pp. 530-536
-
-
Van 'T Veer, L.J.1
Dai, H.2
Van De Vijver, M.J.3
-
44
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A, et al., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 5: 663-71.
-
(2009)
J Clin Oncol
, vol.5
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
45
-
-
0033569406
-
Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
-
Golub TR, Slonim DK, Tamayo P, et al., Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 5439: 531-7.
-
(1999)
Science
, vol.5439
, pp. 531-537
-
-
Golub, T.R.1
Slonim, D.K.2
Tamayo, P.3
-
46
-
-
84933557723
-
Clinicopathological indices to predict hepatocellular carcinoma molecular classification
-
In Press
-
Tan PS, Nakagawa S, Goossens N, et al., Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 2015, In Press.
-
(2015)
Liver Int
-
-
Tan, P.S.1
Nakagawa, S.2
Goossens, N.3
-
47
-
-
84898989382
-
Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design
-
Llovet JM, Hernandez-Gea V., Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Can Res 2014; 8: 2072-9.
-
(2014)
Clin Can Res
, vol.8
, pp. 2072-2079
-
-
Llovet, J.M.1
Hernandez-Gea, V.2
-
48
-
-
84954196911
-
Tissue diagnosis of hepatocellular carcinoma
-
S 73
-
Jain D., Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol 2014; S3:S67 -S 73.
-
(2014)
J Clin Exp Hepatol
, pp. S3S67
-
-
Jain, D.1
-
49
-
-
34948821192
-
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver
-
Huang X, Yang C, Luo Y, et al., FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 10: 2501-10.
-
(2007)
Diabetes
, vol.10
, pp. 2501-2510
-
-
Huang, X.1
Yang, C.2
Luo, Y.3
-
50
-
-
84928706270
-
MTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
-
Scheller T, Hellerbrand C, Moser C, et al., mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer 2015; 112: 841-50.
-
(2015)
Br J Cancer
, vol.112
, pp. 841-850
-
-
Scheller, T.1
Hellerbrand, C.2
Moser, C.3
-
51
-
-
84888294592
-
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma
-
Deshmukh M, Hoshida Y., Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma. Hepatology 2013; 6: 2207.
-
(2013)
Hepatology
, vol.6
, pp. 2207
-
-
Deshmukh, M.1
Hoshida, Y.2
-
52
-
-
56949101730
-
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
-
Ho HK, Pok S, Streit S, et al., Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 1: 118-27.
-
(2009)
J Hepatol
, vol.1
, pp. 118-127
-
-
Ho, H.K.1
Pok, S.2
Streit, S.3
-
53
-
-
84885587718
-
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study
-
Llovet JM, Decaens T, Raoul JL, et al., Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 28: 3509-16.
-
(2013)
J Clin Oncol
, vol.28
, pp. 3509-3516
-
-
Llovet, J.M.1
Decaens, T.2
Raoul, J.L.3
-
54
-
-
41149122199
-
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)
-
Cai ZW, Zhang Y, Borzilleri RM, et al., Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 6: 1976-80.
-
(2008)
J Med Chem
, vol.6
, pp. 1976-1980
-
-
Cai, Z.W.1
Zhang, Y.2
Borzilleri, R.M.3
-
55
-
-
84862285959
-
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase
-
Norman RA, Schott AK, Andrews DM, et al., Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem 2012; 11: 5003-12.
-
(2012)
J Med Chem
, vol.11
, pp. 5003-5012
-
-
Norman, R.A.1
Schott, A.K.2
Andrews, D.M.3
|